Mobile app to help rural adolescent girls eat more fruits and vegetables
Mobile Regulation of Craving Training (mROC-T) to Improve Dietary Intake in Rural Adolescent Girls
This study is testing a mobile app to see if it can help rural girls aged 14-18 eat more fruits and vegetables by teaching them how to manage their cravings.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 15 Years to 18 Years |
| Sex | Female |
| Sponsor | University of Wyoming Academic / other |
| Locations | 1 site (Laramie, Wyoming) |
| Trial ID | NCT06723028 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of a mobile app designed to train adolescents in craving regulation to improve their dietary intake of fruits and vegetables. Participants, aged 14-18, will be randomized into either an active intervention group using the app or a control group receiving general food facts. The study will assess changes in healthy eating index scores, body mass index, waist circumference, and blood glucose levels over one year. Participants will engage with the app twice a week and undergo in-person assessments at baseline and after one year.
Who should consider this trial
Good fit: Ideal candidates for this study are biologically female adolescents aged 15 to 18 years who are interested in improving their dietary habits.
Not a fit: Patients who are biologically male or have certain medical conditions affecting growth or glucose metabolism will not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could lead to improved dietary habits and better health outcomes for adolescent girls at risk of obesity and type 2 diabetes.
How similar studies have performed: Other studies have shown promise in using mobile health interventions for dietary improvements, suggesting this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Biologically female * Female gender * Between the ages of 15y and 18y Exclusion Criteria: * Biologically male * Self-identify as male * BMI percentile (for age and sex) \< 5th% * Diagnosis from a medical profession of any of the following conditions, syndromes, diseases that may affect growth, glucose metabolism, blood clotting, cognitive development\*: * Any form of or history of cancer * Any form of diabetes (type I, II, insipidus) * Precocious puberty * Crohn's disease * Congenital heart defect * Cystic fibrosis * Cerebral palsy * Anorexia nervosa * Bulimia nervosa * Active infection * Fever * Hemophilia * Hydrocephalus * intestinal atresia * Jeune syndrome * Klippel-Trénaunay syndrome * Legg-Calvé-Perthes * Long QT syndrome * Muenke syndrome * Myelomeningocele * Necrotizing Enterocolitis * Neutropenia * Non-alcholoic fatty liver diease * Pfeiffer Syndrome * Saethre-Chotzen syndrome * Shwachman-Diamond syndrome * Spinal muscular atrophy * Sturge-Weber syndrome * Ulcerative Colitis * von Willebrand disease * Pancreatitis * Hurler syndrome * Niemann-Pick disease * Tay-Sachs disease * Gaucher disease * Krabbe disease * Zellweger syndrome * Wilson disease * Brachial Plexus Palsy * Brain Abscess or Spinal Abscess * Coarctation of the Aorta * Aortic stenosis * Ventricular septal defect * Patent ductus arteriosus or mitral valve abnormalities * Congenital Adrenal Hyperplasia * Craniofacial Microsomia * Duchenne Muscular Dystrophy * Dyskeratosis Congenita * Galactosemia * Maple syrup urine disease * Phenylketonuria * Turner syndrome * Prader-Wili disease * History of polycystic ovary syndrome * History of thyroid disease (either hyper or hypo) * History of adrenal disease (including Cushing's syndrome, Addison's disease) * Use of medications related to metabolism/weight such as insulin, corticosteroids, growth hormone, sulfonylurea, thiazolidinediones, beta blockers, calcium channel blockers, bupropion, reboxetine, molindone, clozapine, olanzapine, topiramate, zonisamide, valproate, carbamazepine, lithium, hypolipidemic drugs, highly-active antiretroviral therapies
Where this trial is running
Laramie, Wyoming
- University of Wyoming — Laramie, Wyoming, United States (Recruiting)
Study contacts
- Principal investigator: Grace Shearrer, PhD — University of Wyoming
- Study coordinator: Grace Shearrer, PhD
- Email: gshearre@uwyo.edu
- Phone: 3033326334
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.